Janux Therapeutics, Inc. Proceeds from Maturities, Prepayments and Calls of Short-term Investments
Janux Therapeutics, Inc. (JANX) reported Proceeds from Maturities, Prepayments and Calls of Short-term Investments of $227.57 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments · last filed 2026-08-06
- Janux Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2026-06-30 was $106.26M, a 12.18% increase year-over-year.
- Janux Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2026-03-31 was $121.31M, a 287.94% increase year-over-year.
- Janux Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2025-12-31 was $152.93M, a 163.67% increase year-over-year.
- Janux Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for the quarter ending 2025-09-30 was $126.37M, a 179.79% increase year-over-year.
- Janux Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2025 was $405.28M, a 90.35% increase from fiscal 2024.
- Janux Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2024 was $212.91M, a 23.41% decline from fiscal 2023.
- Janux Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2023 was $278.00M, a 22.58% decline from fiscal 2022.
- Janux Therapeutics, Inc. proceeds from maturities, prepayments and calls of short-term investments for fiscal 2022 was $359.10M, a 167.70% increase from fiscal 2021.
| Period end | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 3 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 6 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 9 month | Proceeds from Maturities, Prepayments and Calls of Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $106.26M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $227.57M 10-Q · filed 2026-08-06 | $380.50M derived: sum of 3 quarters · filed 2026-08-06 | $506.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $121.31M 10-Q · filed 2026-05-07 | $274.24M derived: sum of 2 quarters · filed 2026-05-07 | $400.60M derived: sum of 3 quarters · filed 2026-05-07 | $495.32M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $152.93M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $279.29M derived: sum of 2 quarters · filed 2026-02-26 | $374.01M derived: sum of 3 quarters · filed 2026-08-06 | $405.28M 10-K · filed 2026-02-26 |
| 2025-09-30 | $126.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $221.09M derived: sum of 2 quarters · filed 2026-08-06 | $252.36M 10-Q · filed 2025-11-06 | $310.36M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $94.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $125.99M 10-Q · filed 2026-08-06 | $183.99M derived: sum of 3 quarters · filed 2026-08-06 | $229.16M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $31.27M 10-Q · filed 2026-05-07 | $89.27M derived: sum of 2 quarters · filed 2026-05-07 | $134.44M derived: sum of 3 quarters · filed 2026-05-07 | $179.19M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $58.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $103.17M derived: sum of 2 quarters · filed 2026-02-26 | $147.91M derived: sum of 3 quarters · filed 2026-02-26 | $212.91M 10-K · filed 2026-02-26 |
| 2024-09-30 | $45.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $89.92M derived: sum of 2 quarters · filed 2025-11-06 | $154.91M 10-Q · filed 2025-11-06 | $199.66M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $44.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $109.75M 10-Q · filed 2025-08-07 | $154.50M derived: sum of 3 quarters · filed 2026-02-26 | $229.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $65.00M 10-Q · filed 2025-05-08 | $109.75M derived: sum of 2 quarters · filed 2026-02-26 | $184.75M derived: sum of 3 quarters · filed 2026-02-26 | $279.75M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $44.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $119.75M derived: sum of 2 quarters · filed 2026-02-26 | $214.75M derived: sum of 3 quarters · filed 2026-02-26 | $278.00M 10-K · filed 2026-02-26 |
| 2023-09-30 | $75.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $170.00M derived: sum of 2 quarters · filed 2024-11-06 | $233.25M 10-Q · filed 2024-11-06 | $319.75M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $95.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $158.25M 10-Q · filed 2024-08-07 | $244.75M derived: sum of 3 quarters · filed 2025-02-27 | $361.50M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $63.25M 10-Q · filed 2024-05-08 | $149.75M derived: sum of 2 quarters · filed 2025-02-27 | $266.50M derived: sum of 3 quarters · filed 2025-02-27 | $345.25M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $86.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $203.25M derived: sum of 2 quarters · filed 2025-02-27 | $282.00M derived: sum of 3 quarters · filed 2025-02-27 | $359.10M 10-K · filed 2025-02-27 |
| 2022-09-30 | $116.75M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $195.50M derived: sum of 2 quarters · filed 2023-11-07 | $272.60M 10-Q · filed 2023-11-07 | $384.60M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $78.75M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $155.85M 10-Q · filed 2023-08-08 | $267.85M derived: sum of 3 quarters · filed 2023-08-08 | $290.00M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $77.10M 10-Q · filed 2023-05-09 | $189.10M derived: sum of 2 quarters · filed 2023-05-09 | $211.25M derived: sum of 3 quarters · filed 2023-05-09 | $211.25M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $112.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $134.15M derived: sum of 2 quarters · filed 2023-03-10 | $134.15M derived: sum of 3 quarters · filed 2023-03-10 | $134.15M 10-K · filed 2023-03-10 |
| 2021-09-30 | $22.14M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $22.14M derived: sum of 2 quarters · filed 2022-11-10 | $22.14M 10-Q · filed 2022-11-10 | $22.14M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $0.00 10-Q · filed 2022-08-09 | $0.00 derived: sum of 3 quarters · filed 2022-08-09 | |
| 2021-03-31 | $0.00 10-Q · filed 2022-05-10 | $0.00 derived: sum of 2 quarters · filed 2022-05-10 | ||
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $0.00 10-K · filed 2022-03-18 | ||
| 2020-09-30 | $0.00 10-Q · filed 2021-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |